Please upgrade your browser.
Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC
Dr de Velasco talks to ecancertv at ASCO GU 2016 about analysing when VEGF-targeted therapy for metastatic renal cell carcinoma (mRCC) is discontinued.
Exelixis announced that it has completed the submission of its rolling New Drug Application (NDA) with the Food and Drug Administration (FDA) and requested Priority Review for cabozantinib (tablet formulation) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
HealthWell fund will provide financial assistance to under-insured patients with renal cell carcinoma.
To this day, there is no evidence that the Coalition has any proper third-party auditing of its funding practices, despite repeated requests.
Polycystic kidney disease (PKD) is one of the most common inherited diseases—a parent with PKD has a 50 percent chance of passing the disease on to their child.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.
Michael Lawing, now 67, wasn't much for going to the doctor. Born and raised in Spindale, North Carolina, he always felt so healthy that he didn't see a need.
#GivingTuesday raised a total of $2,620 for kidney cancer research, education, and advocacy. Thanks to all who contributed!
Some potentially good news for all you carnivores out there: A new study shows meat itself might not cause cancer. It could be how you cook it.
Presentation of results from a University of Utah (Huntsman Cancer Institute)-led research study at the 14th International Kidney Cancer Symposium in Miami, Florida, on November 7th, 2015.
|Powered by NeonCRM|